Advagene Biopharma Co., Ltd.

TPEX:6709 Voorraadrapport

Marktkapitalisatie: NT$1.3b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Advagene Biopharma Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yu-Shen Hsu

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO2.2yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Mar 24
Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

Dec 10
Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

CEO

Yu-Shen Hsu

2.2yrs

Tenure

Mr. Yu-Shen Hsu serves as Chairman of Advagene biopharma Co.,Ltd since August 2022 and has been its Acting President, General Manager and Director.